A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 466-479

  Kempsford, Rodger ^a   Allen, Ann ^a   Kelly, Kathryn ^a   Saggu, Parminder ^b   Crim, Courtney ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Betaplex ^*  (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

fluticasone furoate; healthy subjects; moxifloxacin; thorough QT; vilanterol

Indexed keywords

FLUTICASONE FUROATE; HEALTHY SUBJECTS; MOXIFLOXACIN; THOROUGH QT; VILANTEROL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GLUCOCORTICOIDS; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; LONDON; LONG QT SYNDROME; MALE; MIDDLE AGED; RISK ASSESSMENT; YOUNG ADULT;

EID: 84894452245     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12243     Document Type: Article

References (49)

1. Global Initiative for Asthma (GINA) [internet]. Global strategy for asthma management and prevention. 2011. Available at http://www.ginasthma.org (last accessed 11 October 2012).
2. National Heart, Lung and Blood Institute (NHLBI) [internet]. National asthma education and prevention program expert panel report 2: guidelines for the diagnosis and management of asthma. 2011. Available at http://www.nhlbi.nih. gov (last accessed 11 October 2012).
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [internet]. Global strategy for diagnosis, management and prevention of COPD. The Global Initiative for Chronic Obstructive Lung Disease. 2011. Available at http://www.goldcopd.com (last accessed 11 October 2012).
4. Bateman ED, Bleecker ER, Busse W, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WM,. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012; 106: 642-650.
5. Bleecker ER, Bateman ED, Busse W, Lötvall J, Woodcock A, Tomkins S, House K, Jacques L, Haumann B,. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Eur Respir J 2010; 36 (Suppl. 54): S204.
6. Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A,. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012; 67: 35-41.
7. Woodcock A, Bateman ED, Busse W, Lötvall J, Snowise N, Forth R, Jacques L, Haumann B, Bleecker ER,. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res 2011; 12: 132.
8. Lötvall J, Bateman ED, Bleecker ER, Busse W, Woodcock A, Follows R, Lim J, Stone S, Jacques L, Haumann B,. 24h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs. Eur Respir J 2012; 40: 570-579.
9. 2 agonist (LABA), vilanterol trifenatate (VI), in adults with persistent asthma. Respir Med 2012; 106: 1110-1115.
10. 2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012; 142: 119-127.
11. 2-adrenoreceptor agonist. Core Evid 2009; 4: 37-41.
12. Sears MR, Lötvall J,. Past, present and future-beta2-adrenoceptor agonists in asthma management. Respir Med 2005; 99: 152-170.
13. LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M,. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 2008; 63: 103-111.
14. Cazzola M, Matera MG,. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34: 757-769.
15. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H,. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010; 10: 1.
16. Salpeter SR, Thomas TM, Salpeter EE,. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest 2004; 125: 2309-2321.
17. Milic M, Bao X, Rizos D, Liu F, Ziegler MG,. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist- induced QTc prolongation. Clin Ther 2006; 28: 582-590.
18. US Department of Health and Human Services Food and Drug Administration (FDA) [internet]. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Food and Drug Administration. 2005. Available at http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm129357.pdf (last accessed 11 October 2012).
19. European Medicines Agency (EMEA) [internet]. ICH Topic E14. the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. European Medicines Agency. 2005. Available at http://www.emea.europa.eu/pdfs/human/ich/000204en.pdf (last accessed 11 October 2012).
20. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC,. Lung volumes and forced ventilatory flows. Report working party: standardization of lung function testing. Eur Respir J 1993; 6: 5-40.
21. Avelox® (moxifloxacin) 400 mg film-coated tablets summary of product characteristics [online]. Available at http://www.medicines.org.uk/emc/medicine/ 11841/SPC/avelox%20400%20mg%20film-coated%20tablets (last accessed 11 October 2012).
22. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA,. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008; 84: 475-480.
23. Fridericia LS,. Duration of systole in electrocardiogram. Acta Med Scandinav 1920; 53: 469-486.
24. Bazett HC,. An analysis of time relations of electrocardiograms. Heart 1920; 7: 353-367.
25. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ,. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87: 220-228.
26. Batchvarov VN, Ghurun A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M,. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282: H2356-2363.
27. Health Canada [internet]. Revised guide for the analysis and review of QT/QTc interval data. 2010. Available at http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guideld/qtqtc/qt-review-examen-eng.php#rate (last accessed 12 October 2012).
28. CredibleMeds™ [internet]. Drug lists by risk groups. Drugs that prolong the QT interval and/or induce Torsades de Pointes. Available at http://www.azcert.org/ (last accessed 2 November 2012).
29. Beal SL, Sheiner LB, Boeckmann AJ, (University of California, San Francisco CA). NONMEM Users Guide, Part V. Introductory Guide. San Francisco, CA: NONMEM Project Group, 1994.
30. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamics model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
31. Post TM, Freijer JI, Ploeger BA, Manhof M,. Extensions to the Visual Predictive Check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202.
32. Vitasalo M, Karjalainen J,. QT intervals at heart rates from 50 to 120 beats per minute during 24-hour electrocardiographic recordings in 100 healthy men. Effects of atenolol. Circulation 1992; 86: 1439-1442.
33. Malik M,. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12: 411-420.
34. Darpo B,. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 2010; 159: 49-57.
35. Salvi V, Karnad DR, Panicker GK, Kothari S,. Update on the evaluation of a new drug for effects of cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2010; 159: 34-48.
36. Kempsford R, Norris V, Siederer S,. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2013; 26: 256-264.
37. MacNee W,. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013; 45: 291-300.
38. Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C,. A randomised trial of fluticasone fuorate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013; 107: 560-569.
39. Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PMA,. Fluticasone furoate/vilanterol (100/25; 200/25 ug) improves lung function in COPD: a randomised trial. Respir Med 2013; 107: 550-559.
40. Busse WW, O'Byrne PM, Bleecker ER, Lotvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED,. Safety and tolerability of the novel inhaled corticosteroid fluticasone fuorate in combination with the b2 agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma: a randomised trial. Thorax 2013; 68: 513-520.
41. Allen A, Bareille PJ, Rousell VM,. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013; 52: 37-42.
42. Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF,. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulmonary Medicine 2011; 11: 31.
43. Onbrez® Breezhaler® (indacaterol maleate) 150 mcg and 300 mcg inhalation powder, hard capsules, summary of product characteristics [online]. Available at http://www.medicines.org.uk/EMC/medicine/23260/SPC/ Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder,+hard+capsules (last accessed 11 October 2012).
44. Kempsford R, Allen A, Bareille P, Bishop H, Hamilton M, Cheesbrough A,. The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. Eur Respir J 2011; 38 (Suppl. 55): S138.
45. Stylianou A, Roger J, Stephens KA,. Statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies. J Biopharm Stat 2008; 18: 502-516.
46. Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, Rousell VM,. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos 2008; 36: 2337-2344.
47. 2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos 2013; 41: 89-100.
48. Allen A, Davis A, Hardes K, Tombs L, Kempsford R,. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodymanic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther 2012; 34: 2316-2332.
49. Kempsford R, Allen A, Rubin D, Bal J, Tombs L,. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol in healthy subjects. Br J Clin Pharmacol 2013; 75: 1478-1487